99久久精品免费观看国产,色网站免费,2021国内精品久久久久久影院,国产免费福利网站,欧美日韩国产精品综合,国内在线精品,国产三级日本三级日产三

CN / EN

News

Technoderma Medicines Dosed TDM-105795 in Phase 1b (MAD) AGA Clinical Trial

Release time: 2022-03-11 Article source: 特科羅

SHANGHAI – February 23 2022  Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing in its Phase 1b (MAD) clinical trial of topical TDM-105795 solution in patients with Androgenetic Alopecia (AGA). This second clinical trial in the program is a 28-day multiple dose escalation study entitled, “A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects with Androgenetic Alopecia”. Study objectives are to evaluate the safety and pharmacokinetics of topical TDM-105795 following repeated doses. Two U.S. clinical sites are currently participating in this study.

Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We also expect the current study results to guide choice of formulation strength(s) appropriate for a subsequent proof-of-concept (PoC) Phase 2 Androgenetic Alopecia study. The Company anticipates the robust induction of hair growth demonstrated by TDM-105795 in preclinical testing should be observable within several months of initiating treatment.”

“We look to the TDM-105795 AGA program as the first clinical anchor among our pipeline products for treatment of various dermatologic diseases,” said Zengquan Wang, Chief Executive Officer at Technoderma Medicines. “We are working tobring a second pipeline product (Atopic Dermatitis) into clinical testing soon in mid-year.”


郧西县| 友谊县| 如东县| 松溪县| 南投市| 怀化市| 乌拉特前旗| 望都县| 甘谷县| 玉田县| 剑阁县| 大渡口区| 博湖县| 宜宾市| 鸡西市| 搜索| 四会市| 安阳县| 德安县| 遵化市| 津南区| 山东| 榆中县| 旺苍县| 临洮县| 从化市| 温州市| 德阳市| 基隆市| 枝江市| 四子王旗| 深水埗区| 舟山市| 上虞市| 镇宁| 伊宁县| 合水县| 石嘴山市| 肇州县| 津市市| 工布江达县|